France's SpineGuard FY 2025 revenue falls 19% amid cost structure adaptation

Spineguard SA

20/01/2026 02:10

Overview

France-based surgical guidance firm's FY 2025 revenue fell 19%, missing analyst expectations

Company's Q4 revenue grew 13% sequentially from Q3 2025, though it declined 16% y/y

SpineGuard transforming U.S. business model with Omnia Medical partnership

Outlook

SpineGuard aims to achieve operational break-even by end of 2026

Company is transforming US business model to improve margins

SpineGuard expects to cover financing needs until Q4 2026

Result Drivers

COST STRUCTURE ADAPTATION - Co said actions to adapt cost structure in 2025, particularly in the U.S., improved operating performance but temporarily impacted revenue

BUSINESS MODEL TRANSITION - Co's transition in U.S. business model with Omnia Medical led to short-term revenue decline but aims for improved margins and synergies

REGIONAL GROWTH VARIATION - Revenue grew in Europe and Asia, offset by declines in Latin America and Middle East; significant order expected in Saudi Arabia in H1 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
Miss
EUR 3.76 mln
EUR 4.56 mln (1 Analyst)

Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Spineguard SA is €0.63, about 483.3% above its January 16 closing price of €0.11

Press Release: ID:nBw4GHzzTa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)